Skip to main content
Erschienen in: Medical Oncology 4/2012

01.12.2012 | Original Paper

Clinicopathologic characteristics and prognosis for molecular subtypes in low-grade breast carcinoma: comparison with grade one invasive ductal carcinoma-not otherwise specified

verfasst von: Shuling Wang, Weidong Li, Ning Liu, Tongxian Zhang, Han Liu, Junjun Liu, Fen Liu, Wei Zhang, Estifanos P. Gebreamlak, Yun Niu

Erschienen in: Medical Oncology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to investigate the clinicopathologic characteristics and prognosis value for molecular subtypes of low-grade breast carcinoma (LGBC) compared with grade one invasive ductal carcinoma-not otherwise specified (G1-IDC-NOS). A retrospective review of 688 LGBC and 1 037 G1-IDC-NOS patients was classified into four different molecular subtypes based on the IHC-based definitions for ER, PR, and c-erbB-2. In LGBC, lymph node metastasis, the percentage of III/IV TNM stages, the expression of Ki-67 and p53 in luminal A subtype were lower than in other subtypes (P < 0.01). In addition, the variations of Ki-67 and p53 expression were observed in different subtypes of G1-IDC-NOS (P < 0.01). Compared with G1-IDC-NOS, LGBC has higher proportion in the ER positive, PR positive, HER-2 negative, luminal A subtype, Ki-67 negative, and lymph nodes negative group (P < 0.01). Furthermore, the overall survival of luminal A and luminal B is higher than triple-negative and HER-2/neu subtype both in LGBC and G1-IDC-NOS in 262 LGBC and 330 G1-IDC-NOS patients with proper follow-up. The classification of molecular subtype together with clinicopathologic factors can significantly improve the traditional prognosticators in predicting outcome for LGBC and G1-IDC-NOS. And it may contribute to guide the treatment for LGBC and G1-IDC-NOS in the future.
Literatur
1.
Zurück zum Zitat Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50(1):7–33.PubMedCrossRef Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50(1):7–33.PubMedCrossRef
2.
Zurück zum Zitat Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.PubMedCrossRef Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.PubMedCrossRef
3.
Zurück zum Zitat Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678–85.PubMedCrossRef Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678–85.PubMedCrossRef
4.
Zurück zum Zitat Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.PubMedCrossRef Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.PubMedCrossRef
5.
Zurück zum Zitat Sinn HP. Breast cancer precursors: lessons learned from molecular genetics. J Mol Med (Berl). 2009;87(2):113–5.CrossRef Sinn HP. Breast cancer precursors: lessons learned from molecular genetics. J Mol Med (Berl). 2009;87(2):113–5.CrossRef
6.
Zurück zum Zitat Abdel-Fatah TM, Powe DG, Hodi Z, et al. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 2007;31(3):417–26.PubMedCrossRef Abdel-Fatah TM, Powe DG, Hodi Z, et al. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 2007;31(3):417–26.PubMedCrossRef
7.
Zurück zum Zitat Abdel-Fatah TM, Powe DG, Hodi Z, et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol. 2008;32(4):513–23.PubMedCrossRef Abdel-Fatah TM, Powe DG, Hodi Z, et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol. 2008;32(4):513–23.PubMedCrossRef
8.
Zurück zum Zitat Page DL, Jensen RA, Simpson JF, Dupont WD. Historical and epidemiologic background of human premalignant breast disease. J Mammary Gland Biol Neoplasia. 2000;5(4):341–9.PubMedCrossRef Page DL, Jensen RA, Simpson JF, Dupont WD. Historical and epidemiologic background of human premalignant breast disease. J Mammary Gland Biol Neoplasia. 2000;5(4):341–9.PubMedCrossRef
9.
Zurück zum Zitat Tavassoli FA, Eusebi V.AFIP Atlas of tumor pathology, series 4 (Tumors of the mammary gland). Washington, DC: American Registry of Pathology and Armed Force Institute of Pathology,2009:54–71. Tavassoli FA, Eusebi V.AFIP Atlas of tumor pathology, series 4 (Tumors of the mammary gland). Washington, DC: American Registry of Pathology and Armed Force Institute of Pathology,2009:54–71.
10.
Zurück zum Zitat Kim MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006;37(9):1217–26.PubMedCrossRef Kim MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006;37(9):1217–26.PubMedCrossRef
11.
Zurück zum Zitat Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24(36):5652–7.PubMedCrossRef Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24(36):5652–7.PubMedCrossRef
12.
Zurück zum Zitat Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25–32.PubMedCrossRef Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25–32.PubMedCrossRef
13.
Zurück zum Zitat Blackman DJ, Masi CM. Racial and ethnic disparities in breast cancer mortality: are we doing enough to address the root causes? J Clin Oncol. 2006;24(14):2170–8.PubMedCrossRef Blackman DJ, Masi CM. Racial and ethnic disparities in breast cancer mortality: are we doing enough to address the root causes? J Clin Oncol. 2006;24(14):2170–8.PubMedCrossRef
14.
Zurück zum Zitat Tavassoli FA, Devilee P. Pathology and genetics of tumors of the breast and female genital organs. World Health Organization classification of tumors. Lyon: IARC Press; 2003. Tavassoli FA, Devilee P. Pathology and genetics of tumors of the breast and female genital organs. World Health Organization classification of tumors. Lyon: IARC Press; 2003.
15.
Zurück zum Zitat Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95.PubMedCrossRef Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95.PubMedCrossRef
16.
Zurück zum Zitat Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–45.PubMedCrossRef Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–45.PubMedCrossRef
17.
Zurück zum Zitat Jacquemier J, Charafe-Jauffret E, Monville F, et al. Association of GATA3, P53, Ki-67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res. 2009;11(2):R23.PubMedCrossRef Jacquemier J, Charafe-Jauffret E, Monville F, et al. Association of GATA3, P53, Ki-67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res. 2009;11(2):R23.PubMedCrossRef
18.
Zurück zum Zitat Colleoni M, Viale G, Zahrieh D, et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol. 2008;19(3):465–72.PubMedCrossRef Colleoni M, Viale G, Zahrieh D, et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol. 2008;19(3):465–72.PubMedCrossRef
19.
Zurück zum Zitat Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 2004;91(4):639–43.PubMed Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 2004;91(4):639–43.PubMed
20.
Zurück zum Zitat Zhao J, Liu H, Wang M, et al. Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. J Surg Oncol. 2009;100(2):89–94.PubMedCrossRef Zhao J, Liu H, Wang M, et al. Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. J Surg Oncol. 2009;100(2):89–94.PubMedCrossRef
21.
Zurück zum Zitat Lopez-Garcia MA, Geyer FC, Natrajan R, et al. Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas. J Pathol. 2010;222(1):64–75.PubMed Lopez-Garcia MA, Geyer FC, Natrajan R, et al. Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas. J Pathol. 2010;222(1):64–75.PubMed
22.
Zurück zum Zitat Rakha EA, Lee AH, Evans AJ, et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol. 2010;28(1):99–104.PubMedCrossRef Rakha EA, Lee AH, Evans AJ, et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol. 2010;28(1):99–104.PubMedCrossRef
23.
Zurück zum Zitat Ademuyiwa FO, Thorat MA, Jain RK, Nakshatri H, Badve S. Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low oncotype DX 21-gene recurrence scores. Mod Pathol. 2010;23(2):270–5.PubMedCrossRef Ademuyiwa FO, Thorat MA, Jain RK, Nakshatri H, Badve S. Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low oncotype DX 21-gene recurrence scores. Mod Pathol. 2010;23(2):270–5.PubMedCrossRef
24.
Zurück zum Zitat Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279.PubMedCrossRef Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279.PubMedCrossRef
25.
Zurück zum Zitat Sanchez-Munoz A, Garcia-Tapiador AM, Martinez-Ortega E, et al. Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Transl Oncol. 2008;10(10):646–53.PubMedCrossRef Sanchez-Munoz A, Garcia-Tapiador AM, Martinez-Ortega E, et al. Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Transl Oncol. 2008;10(10):646–53.PubMedCrossRef
26.
Zurück zum Zitat Tovey SM, Brown S, Doughty JC, et al. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer. 2009;100(5):680–3.PubMedCrossRef Tovey SM, Brown S, Doughty JC, et al. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer. 2009;100(5):680–3.PubMedCrossRef
27.
Zurück zum Zitat Potemski P, Kusinska R, Watala C, et al. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology. 2005;69(6):478–85.PubMedCrossRef Potemski P, Kusinska R, Watala C, et al. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology. 2005;69(6):478–85.PubMedCrossRef
28.
Zurück zum Zitat Ambs S. Prognostic significance of subtype classification for short- and long-term survival in breast cancer: survival time holds the key. PLoS Med. 2010;7(5):e1000281.PubMedCrossRef Ambs S. Prognostic significance of subtype classification for short- and long-term survival in breast cancer: survival time holds the key. PLoS Med. 2010;7(5):e1000281.PubMedCrossRef
29.
Zurück zum Zitat Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer. 2010;17(4):R245–62.PubMedCrossRef Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer. 2010;17(4):R245–62.PubMedCrossRef
30.
Zurück zum Zitat Lacroix-Triki M, Suarez PH, MacKay A, et al. Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol. 2010;222(3):282–98.PubMedCrossRef Lacroix-Triki M, Suarez PH, MacKay A, et al. Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol. 2010;222(3):282–98.PubMedCrossRef
31.
Zurück zum Zitat Esposito NN, Chivukula M, Dabbs DJ. The ductal phenotypic expression of the E-cadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study. Mod Pathol. 2007;20(1):130–8.PubMedCrossRef Esposito NN, Chivukula M, Dabbs DJ. The ductal phenotypic expression of the E-cadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study. Mod Pathol. 2007;20(1):130–8.PubMedCrossRef
Metadaten
Titel
Clinicopathologic characteristics and prognosis for molecular subtypes in low-grade breast carcinoma: comparison with grade one invasive ductal carcinoma-not otherwise specified
verfasst von
Shuling Wang
Weidong Li
Ning Liu
Tongxian Zhang
Han Liu
Junjun Liu
Fen Liu
Wei Zhang
Estifanos P. Gebreamlak
Yun Niu
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0174-3

Weitere Artikel der Ausgabe 4/2012

Medical Oncology 4/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.